SG11201807857PA - Immunocompetent cell and expression vector expressing regulatory factors of immune function - Google Patents
Immunocompetent cell and expression vector expressing regulatory factors of immune functionInfo
- Publication number
- SG11201807857PA SG11201807857PA SG11201807857PA SG11201807857PA SG11201807857PA SG 11201807857P A SG11201807857P A SG 11201807857PA SG 11201807857P A SG11201807857P A SG 11201807857PA SG 11201807857P A SG11201807857P A SG 11201807857PA SG 11201807857P A SG11201807857P A SG 11201807857PA
- Authority
- SG
- Singapore
- Prior art keywords
- cell
- immune function
- regulatory factors
- immunocompetent
- immunocompetent cell
- Prior art date
Links
- 230000036737 immune function Effects 0.000 title abstract 3
- 102000037983 regulatory factors Human genes 0.000 title abstract 3
- 108091008025 regulatory factors Proteins 0.000 title abstract 3
- 239000013604 expression vector Substances 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 7
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 102000000704 Interleukin-7 Human genes 0.000 abstract 2
- 108010002586 Interleukin-7 Proteins 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 229940100994 interleukin-7 Drugs 0.000 abstract 2
- 102100036842 C-C motif chemokine 19 Human genes 0.000 abstract 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000035899 viability Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
It is to provide an immunocompetent cell that expresses regulatory factors of i mmunocompetent cell immune function and posses ses all of proliferative potential, viability, and the ability to accumulate a T cell, and an ex pression vector of regulatory factors of immune function for generating the immunocompetent cell. An immunocompetent cell expressing a cell surface molecule specifically recognizing a cancer antigen, interleukin 7 (IL-7), and CCL19 is generated. Preferably, the cell surface molecule specifically recognizing a cancer antigen is T cell rece ptor specifically re cognizing the cancer antigen, and the immunocompetent cell is a T cell.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016053913 | 2016-03-17 | ||
| PCT/JP2017/010437 WO2017159736A1 (en) | 2016-03-17 | 2017-03-15 | Immunocompetent cell and expression vector expressing regulatory factors of immune function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807857PA true SG11201807857PA (en) | 2018-10-30 |
Family
ID=59851517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807857PA SG11201807857PA (en) | 2016-03-17 | 2017-03-15 | Immunocompetent cell and expression vector expressing regulatory factors of immune function |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11337997B2 (en) |
| EP (1) | EP3431597A4 (en) |
| JP (4) | JP6561372B2 (en) |
| KR (3) | KR102495308B1 (en) |
| CN (2) | CN109153989B (en) |
| AU (1) | AU2017235116B2 (en) |
| BR (1) | BR112018068314A2 (en) |
| CA (1) | CA3017442A1 (en) |
| IL (1) | IL261707A (en) |
| MX (2) | MX2018010974A (en) |
| MY (1) | MY190565A (en) |
| NZ (1) | NZ746168A (en) |
| PH (1) | PH12018550156A1 (en) |
| RU (1) | RU2770812C2 (en) |
| SG (1) | SG11201807857PA (en) |
| TW (2) | TW202313966A (en) |
| WO (1) | WO2017159736A1 (en) |
| ZA (1) | ZA201805913B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109153989B (en) * | 2016-03-17 | 2022-10-28 | 国立大学法人山口大学 | Immune active cell for expressing immune function regulating factor and expression vector |
| US11447562B2 (en) | 2017-01-01 | 2022-09-20 | Chi-Yu Gregory Lee | RP215 chimeric antigen receptor construct and methods of making and using same |
| US20210122831A1 (en) * | 2017-03-27 | 2021-04-29 | Noile-Immune Biotech, Inc. | Chimeric antigen receptor |
| EP4265634A3 (en) | 2017-10-10 | 2024-01-24 | National University Corporation Tottori University | Enhancer for t-cells or b-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in t-cells or b-cells |
| WO2019124468A1 (en) * | 2017-12-24 | 2019-06-27 | ノイルイミューン・バイオテック株式会社 | Immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, il-7 and ccl19 |
| EP3822345A4 (en) | 2018-05-15 | 2022-06-29 | Cafa Therapeutics Limited | Genetically engineered cell and application thereof |
| AU2020373899A1 (en) * | 2019-10-28 | 2022-06-09 | Noile-Immune Biotech Inc. | Drug for treating cancer, combination drug, drug composition, immune responsive cell, nucleic acid delivery vehicle, and product |
| CN111849910B (en) * | 2020-05-27 | 2021-06-15 | 南京北恒生物科技有限公司 | Engineered immune cells and uses thereof |
| AU2022312311A1 (en) | 2021-07-16 | 2024-02-08 | Noile-Immune Biotech Inc. | Anti-EGFRviii antibody, polypeptide, cell capable of expressing said polypeptide, pharmaceutical composition comprising said cell, method for producing said cell, and polynucleotide or vector comprising nucleotide sequence encoding said polypeptide |
| WO2023286841A1 (en) | 2021-07-16 | 2023-01-19 | ノイルイミューン・バイオテック株式会社 | Chimeric antigen receptor, cell capable of expressing said receptor, pharmaceutical composition containing said cell, method for producing said cell, and polynucleotide or vector which contains nucleotide sequence encoding said chimeric antigen receptor |
| WO2023007431A1 (en) * | 2021-07-29 | 2023-02-02 | Takeda Pharmaceutical Company Limited | Engineered immune cell that specifically targets mesothelin and uses thereof |
| CN115704010A (en) * | 2021-08-11 | 2023-02-17 | 南京北恒生物科技有限公司 | Engineered immune cells and uses thereof |
| GB202205572D0 (en) * | 2022-04-14 | 2022-06-01 | Adaptimmune Ltd | Engineered T cells |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2573912C2 (en) * | 2008-10-08 | 2016-01-27 | Интрексон Корпорейшн | Constructed cells, expressing multiple immunomodulators, and thereof application |
| AU2011232435B2 (en) | 2010-03-23 | 2016-01-28 | Intrexon Corporation | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
| LT2649086T (en) * | 2010-12-09 | 2017-11-10 | The Trustees Of The University Of Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP5897035B2 (en) | 2010-12-14 | 2016-03-30 | ユニバーシティ オブ メリーランド，ボルチモア | General-purpose anti-tag chimeric antigen receptor-expressing T cells and methods for treating cancer |
| CN102539745B (en) * | 2010-12-31 | 2013-03-06 | 中国人民解放军第三〇九医院 | Early diagnosis and early warning kit for transplanted kidney rejection reaction and detection method |
| ES2795023T3 (en) * | 2011-09-16 | 2020-11-20 | Baylor College Medicine | Specific recognition of the tumor microenvironment using engineered NKT cells |
| JP6117515B2 (en) | 2011-11-01 | 2017-04-19 | 国立大学法人名古屋大学 | Pharmaceutical composition for meningioma treatment |
| AU2013221672B2 (en) | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013142186A1 (en) * | 2012-03-21 | 2013-09-26 | Dana-Farber Cancer Institute, Inc. | Isolation and use of human lymphoid organ-derived suppressive stromal cells |
| LT3205720T (en) | 2014-10-09 | 2019-12-10 | Univ Yamaguchi | Car expression vector and car-expressing t cells |
| CN109153989B (en) * | 2016-03-17 | 2022-10-28 | 国立大学法人山口大学 | Immune active cell for expressing immune function regulating factor and expression vector |
| CN112226462A (en) * | 2020-10-12 | 2021-01-15 | 广东昭泰体内生物医药科技有限公司 | Expression vector for co-expressing secretory IL-7 and selective CCL19 and application thereof |
-
2017
- 2017-03-15 CN CN201780029948.1A patent/CN109153989B/en active Active
- 2017-03-15 NZ NZ746168A patent/NZ746168A/en unknown
- 2017-03-15 US US16/084,503 patent/US11337997B2/en active Active
- 2017-03-15 AU AU2017235116A patent/AU2017235116B2/en active Active
- 2017-03-15 WO PCT/JP2017/010437 patent/WO2017159736A1/en active Application Filing
- 2017-03-15 EP EP17766732.6A patent/EP3431597A4/en active Pending
- 2017-03-15 RU RU2018135652A patent/RU2770812C2/en active
- 2017-03-15 MY MYPI2018703180A patent/MY190565A/en unknown
- 2017-03-15 BR BR112018068314A patent/BR112018068314A2/en active Search and Examination
- 2017-03-15 KR KR1020207034092A patent/KR102495308B1/en active IP Right Grant
- 2017-03-15 MX MX2018010974A patent/MX2018010974A/en unknown
- 2017-03-15 KR KR1020237001960A patent/KR20230017358A/en not_active Application Discontinuation
- 2017-03-15 KR KR1020187029397A patent/KR102186180B1/en active IP Right Grant
- 2017-03-15 JP JP2018505978A patent/JP6561372B2/en active Active
- 2017-03-15 CN CN202211222315.1A patent/CN115896120A/en active Pending
- 2017-03-15 CA CA3017442A patent/CA3017442A1/en active Pending
- 2017-03-15 SG SG11201807857PA patent/SG11201807857PA/en unknown
- 2017-03-16 TW TW111147302A patent/TW202313966A/en unknown
- 2017-03-16 TW TW106108741A patent/TWI789348B/en active
-
2018
- 2018-09-04 ZA ZA2018/05913A patent/ZA201805913B/en unknown
- 2018-09-11 MX MX2023005317A patent/MX2023005317A/en unknown
- 2018-09-12 PH PH12018550156A patent/PH12018550156A1/en unknown
- 2018-09-12 IL IL261707A patent/IL261707A/en unknown
-
2019
- 2019-07-01 JP JP2019122746A patent/JP6884423B2/en active Active
-
2021
- 2021-04-30 JP JP2021077128A patent/JP2021121198A/en active Pending
-
2022
- 2022-05-19 US US17/748,889 patent/US11931381B2/en active Active
-
2023
- 2023-01-11 JP JP2023002047A patent/JP2023029553A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807857PA (en) | Immunocompetent cell and expression vector expressing regulatory factors of immune function | |
| ZA202206078B (en) | Anti-cd3 antibodies and methods of use | |
| PH12018502400A1 (en) | Anti-tim-3 antibodies and methods of use thereof | |
| MX2017005344A (en) | Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy. | |
| MX2019006340A (en) | Anti-ctla-4 antibodies and methods of use thereof. | |
| MX2021003704A (en) | Heterodimeric antibodies that bind cd3 and tumor antigens. | |
| SG10201903912XA (en) | Delivery of biomolecules to immune cells | |
| PH12018501453A1 (en) | Chimeric proteins and methods of immuno therapy | |
| MX2023000818A (en) | Anti-ctla-4 antibodies and methods of use thereof. | |
| EA201790624A1 (en) | AIMING OF CYTOTOXIC CELLS WITH CHEMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY | |
| MX2016010345A (en) | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells. | |
| MX2017014353A (en) | Heterodimeric antibodies that bind cd3 and tumor antigens. | |
| MX2019012223A (en) | Anti-cd137 antibodies and methods of use thereof. | |
| MA40253A (en) | Engineered cells for adoptive cell therapy | |
| MY186334A (en) | Anti-her2 antibodies and immunoconjugates | |
| MY175869A (en) | Compositions and methods for immunotherapy | |
| PH12019502637A1 (en) | Chimeric antigen receptors targeting flt3 | |
| AU2016335217A8 (en) | Antigen receptors and uses thereof | |
| MX2020004094A (en) | Methods of administering chimeric antigen receptor immunotherapy. | |
| MX2017013859A (en) | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants. | |
| MX2019006852A (en) | Compositions and methods for modulating the immune system. | |
| EP4295914A3 (en) | Genetically-engineered drug resistant t cells and methods of using the same | |
| RU2022109705A (en) | IMMUNOCOMPETE CELL AND EXPRESSION VECTOR EXPRESSING REGULATORY FACTORS OF IMMUNE FUNCTION | |
| MY192384A (en) | Anti-cd3 antibodies and methods of use |